Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Types of Drug Antagonists
Mohamad Ali Salloum, PharmD • March 12, 2022
Share
An Antagonist is a molecule that binds to a certain receptor and LITERALLY does nothing.
It just sits there, preventing an agonist from binding to perform its usual action. [1] Just like an irritating sibling...
However, an antagonist has several ways to annoy the agonist and prevent it from binding to its receptor or do its effect. Let’s explore them...
1) Reversible Competitive antagonists:
It is the most common and usually it sits in place of the agonist. Increasing the concentration of the agonist in the presence of the reversible antagonist will allow its binding to the receptor. And that’s why it is called “Competitive”. There is a competition between the agonist and the antagonist on who will bind to the same receptor, and if the agonist concentration was increased, it will be able to replace the antagonist. Example of a competitive antagonist is naloxone, which is used in emergencies to reverse the life-threatening effects of a known or suspected opiate (narcotic) overdose [2]. Naloxone injection can be also used after surgery to reverse the effects of opiates given during surgery. [3]
2) Irreversible Competitive antagonist:
In this case, increasing the concentration of the agonist in the presence of the irreversible antagonist will have no effect. This happens because the antagonist binds irreversibly to the receptor and there is no concentration from the agonist that can replace it. Note that this kind of antagonism is also called “Competitive” since both molecules compete on the same receptor, however, the irreversible antagonist contain reactive groups that create covalent bonds with the receptor. Usually, these are used as experimental tools to investigate about the receptor function, and few are used clinically. However, irreversible enzyme inhibitors that act similarly are clinically used and include drugs such as aspirin, omeprazole, and monoamine oxidase inhibitors (MAOIs) [4]
3) Allosteric (non-competitive) antagonists:
Allosteric antagonist means that this molecule does not sit necessarily on the receptor itself, but it binds near it and causes some modifications that will prevent the agonist from binding to is receptor, because simply the agonist can’t recognize the receptor (scientifically, we say that the allosteric antagonists reduce the affinity of the agonist toward their receptors). Thus, increasing the concentration of the agonist will have no effect. Example for allosteric antagonist is Ticagrelor, an anti-platelet drug. [5]
4) Physiologic antagonist:
The antagonist binds to a receptor that totally differs from the one that the agonist binds on. The physiologic response that results from the binding of the antagonist will antagonize the effect of the agonist. (Even if this physiologic antagonist is an agonist itself)
For example, histamine acts on Histamine Receptors of the parietal cells of the gastric mucosa to stimulate acid secretion, while omeprazole blocks this effect by inhibiting the proton pump. [4]
5) Chemical Antagonist:
This antagonist will work directly on the agonist itself and not on the receptor (most of the times). The main mechanism here is the binding of this chemical antagonist to the agonist and preventing its binding to its receptors. Examples include the use of chelating agents. (e.g., dimercaprol) that bind to heavy metals and consequently reduce their toxicity. Infliximab, a neutralizing antibody, has an anti-inflammatory action due to its ability to sequester the inflammatory cytokine tumor necrosis factor (TNF). [4]
6) Pharmacokinetic antagonist:
It is the ‘antagonist’ that effectively reduces the concentration of the active drug at its site of action. As we know, the Pharmacokinetic steps are Absorption, Distribution, Metabolism, and Excretion. At every step, if a drug can alter the concentration of the active drug at its site of action, it is considered a pharmacokinetic antagonist. For example, Phenytoin (anti-seizure drug) enhances the hepatic metabolism of warfarin (anti-coagulant drug), which will result in the reduction of the anti-coagulant effect. On the other hand, the rate of absorption of the active drug from the gastrointestinal tract may be reduced, or the rate of renal excretion may be increased. Interactions of this kind are common and can be important in clinical practice.
7) Partial agonists:
These types of molecules, although they are agonists, however, they act as antagonists in the presence of the full agonists (refer to this article to understand difference between full and partial agonists). [4] Example of a partial agonist is Tolazoline and when it is combined with the full agonist Phenylephrine, it acts as an antagonist.
You can also watch the illustrative video below for more understanding of the topic.
Resources:
[1] N. E. Goeders, "Antagonist," 2001. [Online]. Available: https://www.encyclopedia.com/medicine/anatomy-and-physiology/anatomy-and-physiology/antagonist#apaTab0. [Accessed 11 3 2022].
[2] A. M. Sabzghabaee, N. . Eizadi-Mood, A. . Yaraghi and S. . Zandifar, "Naloxone therapy in opioid overdose patients: intranasal or intravenous? A randomized clinical trial," Archives of Medical Science, vol. 10, no. 2, pp. 309-314, 2014.
[3] "Naloxone Hydrochloride," , . [Online]. Available: https://www.drugs.com/monograph/naloxone-hydrochloride.html. [Accessed 12 3 2022].
[4] R. J. F. R. H. G. Rang HP, Rang and Dale's pharmacology, ed., vol. , , : Elsevier, 2016, p. 6–20.
[5] J. J. Nawarskas and S. M. Clark, "Ticagrelor: a novel reversible oral antiplatelet agent.," Cardiology in Review, vol. 19, no. 2, pp. 95-100, 2011.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
References: Qiang S, Wu J, Zheng D, et al. The effect of stress mindset on psychological pain: the chain mediating roles of cognitive reappraisal and self-identity. Front Psychol. 2025;16. 1 Bosshard M, Gomez P. Effectiveness of stress arousal reappraisal and stressisenhancing mindset interventions on task performance outcomes: a meta-analysis. Sci Rep. 2024. 2 Zhao S, Chen P, Jin L, et al. Unlocking Emotional Well-Being: Evaluation of a Stress Mindset Intervention With a Metacognitive Approach. Emotion. 2025;25(5):1169–1184. 4 Meyer HH, Stutts LA. The Effect of Mindset Interventions on Stress and Academic Motivation in College Students. Innov High Educ. 2024;49:783–798. 7 Crum AJ, Santoro E, Handley-Miner I, et al. Evaluation of the “Rethink Stress” Mindset Intervention: A Metacognitive Approach to Changing Mindsets. J Exp Psychol Gen. 2023. 3 Laferton JAC, Fischer S, Ebert DD, et al. The Effects of Stress Beliefs on Daily Affective Stress Responses. Ann Behav Med. 2020;54(4):258–267. 5 UCSF Stress Measurement Network. Beliefs about Stress . 2026. 6 
References: Qiang S, Wu J, Zheng D, et al. The effect of stress mindset on psychological pain: the chain mediating roles of cognitive reappraisal and self-identity. Front Psychol. 2025;16. 1 Bosshard M, Gomez P. Effectiveness of stress arousal reappraisal and stressisenhancing mindset interventions on task performance outcomes: a meta-analysis. Sci Rep. 2024. 2 Zhao S, Chen P, Jin L, et al. Unlocking Emotional Well-Being: Evaluation of a Stress Mindset Intervention With a Metacognitive Approach. Emotion. 2025;25(5):1169–1184. 4 Meyer HH, Stutts LA. The Effect of Mindset Interventions on Stress and Academic Motivation in College Students. Innov High Educ. 2024;49:783–798. 7 Crum AJ, Santoro E, Handley-Miner I, et al. Evaluation of the “Rethink Stress” Mindset Intervention: A Metacognitive Approach to Changing Mindsets. J Exp Psychol Gen. 2023. 3 Laferton JAC, Fischer S, Ebert DD, et al. The Effects of Stress Beliefs on Daily Affective Stress Responses. Ann Behav Med. 2020;54(4):258–267. 5 UCSF Stress Measurement Network. Beliefs about Stress . 2026. 6
A clear, evidence‑based guide to Ramadan fasting, explaining its metabolic, mental, and cardiometabolic benefits, plus practical nutrition, hydration, sleep, and medication strategies for healthy adults and high‑risk patients.
A practical guide to shifting from blaming “human error” to applying ICH GCP E6(R3) system‑level quality, Quality by Design, and risk‑based oversight to prevent repeat deviations in clinical trials.
Learn 5 Whys and Fishbone (Ishikawa) for Root Cause Analysis in clinical research, with practical examples and an interactive quiz—no fluff, just clarity.
A clear, practical guide to CAPA for Clinical Research Associates—covering corrective and preventive actions, real‑world scenarios, and an interactive quiz to reinforce learning.
Boost your health with a simple 30‑minute morning walk backed by science—better heart health, mood, sleep, and energy.
References: Gunes IB, Gunes A. Association Between Eyelid Twitching and Digital Screen Time, Uncorrected Refractive Error, Intraocular Pressure, and Blood Electrolyte Imbalances. Cureus . 2024;16(9):e69249. Available from: https://www.cureus.com/articles/291035-association-between-eyelid-twitching-and-digital-screen-time-uncorrected-refractive-error-intraocular-pressure-and-blood-electrolyte-imbalances Banik R, Miller NR. Chronic myokymia limited to the eyelid is a benign condition. J Neuroophthalmol . 2004;24(4):290–2. Available from: https://scholars.mssm.edu/en/publications/chronic-myokymia-limited-to-the-eyelid-is-a-benign-condition-2 Hallett M. Blepharospasm: recent advances. Neurology . 2002;59(11):1759–60. Available from: https://europepmc.org/abstract/MED/12434791 Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov Disord . 2002;17(1):7–12. Available from: https://europepmc.org/article/MED/11835433 Zeppieri M, Ameer MA, Jahngir MU, Patel BC. Meige Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://europepmc.org/article/MED/30020730 Zhang Y, Adamec I, Habek M. Superior oblique myokymia: a meta-analysis. J Ophthalmol . 2018;2018:7290547. Available from: https://doi.org/10.1155/2018/7290547 Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev . 2020;11:CD004900. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004900.pub2/abstract Khalkhali M. Topiramate-induced persistent eyelid myokymia. Case Rep Psychiatry . 2016;2016:7901085. Available from: https://europepmc.org/articles/PMC4886081/
References: Sen A, Tai XY. Sleep duration and executive function in adults. Curr Neurol Neurosci Rep. 2023;23:801–813. [link.springer.com] Nature Research Intelligence. Sleep deprivation and cognitive performance. Nature Portfolio. 2023. Available from: https://www.nature.com/… [nature.com] Skourti E, Simos P, Zampetakis A, et al. Long-term associations between objective sleep and verbal memory performance. Front Neurosci. 2023;17:1265016. [frontiersin.org] Hauglund NL, Andersen M, Tokarska K, et al. Norepinephrine‑mediated slow vasomotion drives glymphatic clearance during sleep. Cell. 2025;188(3):606‑622.e17. [cell.com] Shirolapov IV, Zakharov AV, Smirnova DA, et al. The role of the glymphatic clearance system in sleep–wake interactions and neurodegeneration. Neurosci Behav Physiol. 2024;54:199–204. [link.springer.com] Kong Y, Yu B, Guan G, et al. Effects of sleep deprivation on sports performance: a systematic review and meta-analysis. Front Physiol. 2025;16:1544286. [frontiersin.org] Gong M, Sun M, Sun Y, et al. Effects of acute sleep deprivation on sporting performance in athletes. Nat Sci Sleep. 2024;16:—. [tandfonline.com] Dean B, Hartmann T, Wingfield G, et al. Sleep restriction between consecutive days of exercise impairs cycling performance. J Sleep Res. 2023;32(3):e13857. [onlinelibr....wiley.com] Mah CD, Mah KE, Kezirian EJ, Dement WC. The effects of sleep extension on athletic performance in collegiate basketball players. Sleep. 2011;34(7):943–950. [psycnet.apa.org] Cunha LA, Costa JA, Marques EA, et al. Impact of sleep interventions on athletic performance: a systematic review. Sports Med Open. 2023;9:58. [link.springer.com] Teece AR, Beaven CM, Argus CK, et al. Daytime naps improve afternoon power and perceptual measures in elite rugby union athletes. Sleep. 2023;46(12):zsad133. [academic.oup.com] Mesas AE, Núñez de Arenas-Arroyo S, Martinez-Vizcaino V, et al. Daytime napping and cognitive/physical sport performance: meta-analysis of RCTs. Br J Sports Med. 2023;57(7):417–27. [bjsm.bmj.com] Haines Roberts SS, Teo WP, Warmington SA. Effects of training and competition on the sleep of elite athletes. Br J Sports Med. 2019;53(8):513–522. [bjsm.bmj.com] Walsh NP, Halson SL, Sargent C, et al. Sleep and the athlete: 2021 expert consensus recommendations. Br J Sports Med. 2021;55(7):356–368. [bjsm.bmj.com] Janse van Rensburg DC, Fowler PM, Racinais S. Practical tips to manage travel fatigue and jet lag in athletes. Br J Sports Med. 2021;55(15):821–822. [bjsm.bmj.com] Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: AASM/SRS consensus statement. Sleep. 2015;38(6):843–844. [aasm.org] Centers for Disease Control and Prevention. FastStats: Sleep in adults. CDC. 2024. Available from: https://www.cdc.gov/sleep/… [cdc.gov]